U.S. markets open in 39 minutes

Avivagen Inc. (VIVXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.31570.0000 (0.00%)
At close: 2:13PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3157
Open0.3157
BidN/A x N/A
AskN/A x N/A
Day's Range0.3157 - 0.3157
52 Week Range0.2900 - 0.5697
Volume1,500
Avg. Volume2,209
Market Cap13.424M
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Avivagen Secures Approval for Use of OxC-beta™ Livestock in Brazil and Signs Distribution Agreement

      Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen") a life sciences corporation focused on developing and commercializing immune-system improving products for livestock, companion animal and human applications, is pleased to announce that it has received approval from The Ministry of Agriculture-Feed Additives Division for the immediate use of OxC-beta™ Livestock in poultry, swine and cattle (beef and dairy) in Brazil. With regulatory approval secured, Avivagen has also signed a distribution agreement with established São Paulo-based Look Chemicals Importacao E Exportacao LTDA for the use of OxC-beta™ Livestock in poultry and swine.

    • Zacks Small Cap Research

      VIVXF: Positive Field Tests in Mexico Leads to Increased Order for OxC-beta™ Livestock…

      By David Bautz, PhD OTC:VIVXF READ THE FULL VIVXF RESEARCH REPORT Business Update Avivagen, Inc. (OTC:VIVXF) is developing products to support animal health, which includes replacing antibiotics in livestock feeds with proprietary compounds that promote the growth and overall health of the animal through support of the host’s innate immune system. Avivagen discovered that β-carotene polymerizes

    • Business Wire

      Avivagen Announces Increase in North American OxC-beta™ Livestock Order Following Successful Dairy Field Tests

      Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen") a life sciences corporation focused on developing and commercializing immune-system improving products for livestock, companion animal and human applications, is pleased to announce that its North American purchase order for OxC-beta™ Livestock, placed in March by Mexico-based Industrias Melder, has been increased from 300 kgs to 2 tonnes. The increase follows the positive results of two dairy animal tests recently conducted by one of Industrias Melder’s key customers.